Innate immune activation as a broad-spectrum biodefense strategy: Prospects and research challenges

被引:54
作者
Hackett, CJ [1 ]
机构
[1] NIAID, Mol & Struct Immunol Sect, Basic Immunol Branch, Div Allergy Immunol & Transplantat,NIH, Bethesda, MD 20892 USA
关键词
innate immune defense; adaptive immune system; vaccination; immunotherapeutic approaches;
D O I
10.1016/S0091-6749(03)02025-6
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Biodefense strategies require protection against a broad and largely unforeseen spectrum of pathogens-the forte of innate immune system defenses-that have evolved over millennia to function within moments of encountering either ancient or newly emerging pathogens. Although constitutive, the innate immune system is activated by the presence of microbes or their products, providing a rationale for a potential biodefense strategy. Both prophylactic and postexposure strategies involving innate immune stimulation have been shown to be plausible to prevent or ameliorate infections in animal models. Innate immune-activating compounds based on conserved microbial components recognized by toll-like molecules and other receptors could be synthesized and delivered like drugs by using an entirely different strategy from conventional vaccination. However, important theoretic and practical questions, emerge about developing and deploying innate immune protective strategies for biodefense. This rostrum discusses prospects and. problems in the overall approach itself. Important topics include microbe-specific issues about innate immune system effectiveness against highly virulent pathogens and general questions, such as whether innate immune responses will be safe and effective if used in a diverse human population of different age groups and with different genetic makeups.
引用
收藏
页码:686 / 694
页数:9
相关论文
共 91 条
[1]   Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3 [J].
Alexopoulou, L ;
Holt, AC ;
Medzhitov, R ;
Flavell, RA .
NATURE, 2001, 413 (6857) :732-738
[2]  
Arnon TI, 2001, EUR J IMMUNOL, V31, P2680, DOI 10.1002/1521-4141(200109)31:9<2680::AID-IMMU2680>3.0.CO
[3]  
2-A
[4]   The Ebola virus VP35 protein functions as a type IIFN antagonist [J].
Basler, CF ;
Wang, XY ;
Mühlberger, E ;
Volchkov, V ;
Paragas, J ;
Klenk, HD ;
Garcia-Sastre, A ;
Palese, P .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (22) :12289-12294
[5]   B-1 and B-2 cell-derived immunoglobulin M antibodies are nonredundant components of the protective response to influenza virus infection [J].
Baumgarth, N ;
Herman, OC ;
Jager, GC ;
Brown, LE ;
Herzenberg, LA ;
Chen, JZ .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (02) :271-280
[6]   Sepsis and evolution of the innate immune response [J].
Beutler, B ;
Poltorak, A .
CRITICAL CARE MEDICINE, 2001, 29 (07) :S2-S6
[7]   Genetic evidence for an interferon-antagonistic function of Rift Valley fever virus nonstructural protein NSs [J].
Bouloy, M ;
Janzen, C ;
Vialat, P ;
Khun, H ;
Pavlovic, J ;
Huerre, M ;
Haller, O .
JOURNAL OF VIROLOGY, 2001, 75 (03) :1371-1377
[8]   Cooperation of toll-like receptor 2 and 6 for cellular activation by soluble tuberculosis factor and Borrelia burgdorferi outer surface protein A lipoprotein:: Role of Toll-interacting protein and IL-1 receptor signaling molecules in Toll-like receptor 2 signaling [J].
Bulut, Y ;
Faure, E ;
Thomas, L ;
Equils, O ;
Arditi, M .
JOURNAL OF IMMUNOLOGY, 2001, 167 (02) :987-994
[9]   Inhibition of interleukin 1 receptor/toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4 [J].
Burns, K ;
Janssens, S ;
Brissoni, B ;
Olivos, N ;
Beyaert, R ;
Tschopp, J .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 197 (02) :263-268
[10]  
*CDCP, 2001, MMWR-MORBID MORTAL W, V50, P1008